Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith W Pratz

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.
Haematologica|November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.
Haematologica|November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Pageof 8